These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30231371)

  • 1. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
    Ascierto PA; Flaherty K; Goff S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
    Steininger J; Gellrich FF; Schulz A; Westphal D; Beissert S; Meier F
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
    Silva IP; Long GV
    Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Immunotherapy Development in Melanoma.
    Eggermont AMM; Crittenden M; Wargo J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
    Margolin K
    Curr Treat Options Oncol; 2016 Sep; 17(9):48. PubMed ID: 27461037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
    Melis C; Rogiers A; Bechter O; van den Oord JJ
    Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single versus combination immunotherapy drug treatment in melanoma.
    Grimaldi AM; Marincola FM; Ascierto PA
    Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
    Ascierto PA; Agarwala SS; Ciliberto G; Demaria S; Dummer R; Duong CPM; Ferrone S; Formenti SC; Garbe C; Halaban R; Khleif S; Luke JJ; Mir LM; Overwijk WW; Postow M; Puzanov I; Sondel P; Taube JM; Thor Straten P; Stroncek DF; Wargo JA; Zarour H; Thurin M
    J Transl Med; 2017 Nov; 15(1):236. PubMed ID: 29145885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Tang T; Eldabaje R; Yang L
    Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
    McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
    Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
    Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
    Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.